| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 3138 | 2016 |
| Tracking the evolution of non–small-cell lung cancer M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ... New England Journal of Medicine 376 (22), 2109-2121, 2017 | 2328 | 2017 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56, 2019 | 2249 | 2019 |
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1818 | 2017 |
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma TR Simpson, F Li, W Montalvo-Ortiz, MA Sepulveda, K Bergerhoff, F Arce, ... Journal of Experimental Medicine 210 (9), 1695-1710, 2013 | 1659 | 2013 |
| Cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism DC Gondek, LF Lu, SA Quezada, S Sakaguchi, RJ Noelle The journal of immunology 174 (4), 1783-1786, 2005 | 1396 | 2005 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1266 | 2017 |
| Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies KS Peggs, SA Quezada, CA Chambers, AJ Korman, JP Allison Journal of Experimental Medicine 206 (8), 1717-1725, 2009 | 1138 | 2009 |
| Cyclooxygenase-dependent tumor growth through evasion of immunity S Zelenay, AG Van Der Veen, JP Böttcher, KJ Snelgrove, N Rogers, ... Cell 162 (6), 1257-1270, 2015 | 1078 | 2015 |
| Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts SA Quezada, TR Simpson, KS Peggs, T Merghoub, J Vider, X Fan, ... Journal of Experimental Medicine 207 (3), 637-650, 2010 | 1028 | 2010 |
| Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021, 2017 | 915 | 2017 |
| CD40/CD154 interactions at the interface of tolerance and immunity SA Quezada, LZ Jarvinen, EF Lind, RJ Noelle Annu. Rev. Immunol. 22 (1), 307-328, 2004 | 888 | 2004 |
| CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells SA Quezada, KS Peggs, MA Curran, JP Allison The Journal of clinical investigation 116 (7), 1935-1945, 2006 | 815 | 2006 |
| Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019 | 802 | 2019 |
| Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition K Litchfield, JL Reading, C Puttick, K Thakkar, C Abbosh, R Bentham, ... Cell 184 (3), 596-614. e14, 2021 | 681 | 2021 |
| Translational implications of tumor heterogeneity M Jamal-Hanjani, SA Quezada, J Larkin, C Swanton Clinical cancer research 21 (6), 1258-1266, 2015 | 589 | 2015 |
| Principles and use of anti-CTLA4 antibody in human cancer immunotherapy KS Peggs, SA Quezada, AJ Korman, JP Allison Current opinion in immunology 18 (2), 206-213, 2006 | 586 | 2006 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 580 | 2018 |
| A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy B Philip, E Kokalaki, L Mekkaoui, S Thomas, K Straathof, B Flutter, ... Blood, The Journal of the American Society of Hematology 124 (8), 1277-1287, 2014 | 462 | 2014 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 445 | 2017 |
Henning WalczakMedical Faculty, University of Cologne / University College London
